Transglutaminase 6

Monoclonal antibody to human TG6 (Beta Barrel 2 Domain, clone XTG29)



Order
Quantity
Price
Status
200 µg 400 € available


Documents
Art. No. A158
Host Mouse
Clone XTG29
Isotype IgG1
Immunogen Human neuronal transglutaminase (full length protein with N-terminal hexahistidin-tag) recombinantly produced in insect cells (Zedira product No. T021).
Specificity Beta Barrel 2 Domain
Appearance liquid
Description The IgG fraction was purified by ion exchange chromatography.
Reagents 75 mM NaCl, 5 mM Tris, pH7.5, 0.025% sodium azide, 50% glycerol.
Application Western-Blotting, ELISA
Working dilutions Optimal dilutions should be determined by the end user.
E.g. for Western-Blotting or ELISA: 1 / 500 to 1 / 5,000 should be suitable.
Storage Store at -80°C.
If storage at -80°C is not possible, storage at ≤ -20°C is recommended. Stable for short term at +4°C.
Delivery is possible at ambient temperature.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATI ONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy